TheraRadar
← Back
Data updated: Jun 28, 2026

AM REGENT

Generics
CardiovascularOncologyNeurology Execution: Fair

AM REGENT is a generic drug manufacturer focused on Cardiovascular, Oncology, Neurology. Key products include INJECTAFER.

1972
Since
76
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
4 Small Molecules

AM REGENT at a Glance

  • Fast trial execution (21 months median completion)

AM REGENT's Key Drugs

AM REGENT's core commercial portfolio centers on INJECTAFER, SODIUM PHOSPHATES, POTASSIUM PHOSPHATES, spanning Cardiovascular and Oncology — its most strategically important drugs approved in the last 15 years.

INJECTAFER
Cardiovascular

Iron Deficiency Anemia

Approved 2013
SODIUM PHOSPHATES
Other

Hypophosphatemia

Approved 2022
POTASSIUM PHOSPHATES
Other

Hypophosphatemia

Approved 2019
CALCIUM CHLORIDE 10%
Other
Approved 2017
MULTRYS
Other
DNA polymerase Approved 2020

AM REGENT's Recent FDA Approvals

AM REGENT secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

AM REGENT's Therapeutic Areas

AM REGENT's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Oncology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 40%
4 drugs
Oncology 20%
2 drugs
Neurology 20%
2 drugs
Gastroenterology 10%
1 drugs
Respiratory 10%
1 drugs

AM REGENT's Top Competitors

AM REGENT's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Respiratory
AZURITY specialty
Cardiovascular, Oncology, Neurology, Respiratory
Bayer big-pharma
Oncology, Cardiovascular, Respiratory

AM REGENT Pipeline Snapshot

Active clinical trials for AM REGENT across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • INJECTAFER leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/1 completed
  • • Speed: 21 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges